#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mitochondrial encephalomyopathy Germ cell cancer Infertility male Thrombotic thrombocytopenic purpura Hairy cell leukaemia recurrent Pelizaeus-Merzbacher disease Usher's syndrome Thrombotic microangiopathy Congenital cystic kidney disease Transplant rejection Glomerulonephritis rapidly progressive Rhabdomyosarcoma Epstein-Barr virus infection Retinopathy of prematurity Adenovirus infection More trials…

    Learn about Rare Diseases

    Aicardi-Goutieres syndrome – Treatment Stevens-Johnson syndrome – Diagnostics Alternating hemiplegia of childhood KBG syndrome – Trials in Disease Pulmonary sarcoidosis – Trials in Disease Factor VIII deficiency – Treatment IgA nephropathy – Life with Disease Biotinidase deficiency Alveolar rhabdomyosarcoma – Treatment Cerebral arteriovenous malformation haemorrhagic More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Eftilagimod Alfa Epirubicin Gsk4011499 GRISNILIMAB SETARITOX GSKVX000000034795 SULBACTAM SODIUM Eltrombopag Padeliporfin Ttf-Ngr Entrectinib Amivantamab Elebsiran Mk-4830 Sodium Hyaluronate SONLICROMANOL HYDROCHLORIDE Polatuzumab Vedotin Arachis Hypogaea Flour ALENDRONATE SODIUM TRIHYDRATE LTX-002 SODIUM Tub-040 More therapies…

    Learn about Your Condition

    Pterygium Spermatocele Polycystic ovarian syndrome Cholangitis sclerosing Papulopustular rosacea Critical illness Embolism Thyroid mass Herpes virus infection Cardiac sarcoidosis Tooth loss Lymphoma Genitourinary tract neoplasm Acute kidney injury Transient ischaemic attack More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. CHU d’Estaing

CHU d’Estaing

1 place Lucie et Raymond Aubrac, Clermont Ferrand, 63100, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness and Safety of Tagraxofusp and Venetoclax for Adults with Untreated Blastic Plasmacytoid Dendritic Cell Neoplasm

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • TAGRAXOFUSP
    • Venetoclax
    France

  • Study on EXL01 for Preventing Crohn’s Disease Recurrence After Surgery in Patients

    Recruiting

    2 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Exl01
    France

  • Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Essential thrombocythaemia
    • Myeloproliferative neoplasm
    • Chronic myeloid leukaemia
    Investigated Drugs:
    • Acetylsalicylic Acid
    • Apixaban
    • Rivaroxaban
    France

  • Study of Pioglitazone and Avelumab Combined with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Complete Cytogenetic Response

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Pioglitazone
    • Avelumab
    France

  • Study Comparing mFOLFIRINOX and Capecitabine or Gemcitabine for Patients with Resected Ampullary Adenocarcinoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Tumour of ampulla of Vater
    Investigated Drugs:
    • Calcium Folinate
    • Capecitabine
    • Fluorouracil
    France

  • Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Rhabdomyosarcoma
    Investigated Drugs:
    • Vinorelbine Tartrate
    • Dactinomycin
    • Doxorubicin
    Austria Belgium Czechia Denmark Finland France +10

  • Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Dinutuximab Beta
    • Busulfan
    • Carboplatin
    Austria Belgium Czechia Denmark Finland France +13

  • Study of Oxaliplatin, Nivolumab, and Trifluridine/Tipiracil for Patients with Advanced Gastric, Esophageal, or Gastroesophageal Junction Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Gastric cancer recurrent
    • Oesophageal carcinoma
    • Gastric cancer
    Investigated Drugs:
    • Levoleucovorin
    • Capecitabine
    • Fluorouracil
    France

  • Study Comparing FOLFIRINOX and Cisplatin-Etoposide for Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma
    Investigated Drugs:
    • Cisplatin
    • Etoposide
    • Fluorouracil
    France

  • Study on Chemotherapy with Levoleucovorin, Capecitabine, and Folinic Acid for Patients Aged 70+ After Stage III Colon Cancer Surgery

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Colon cancer
    Investigated Drugs:
    • Levoleucovorin
    • Capecitabine
    • Fluorouracil
    Belgium France
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!